Roche, PDL expand partnership agreement for Zenapax

Roche announced Tuesday that it is expanding its partnership with Protein Design Labs to co-develop and commercialise Zenapax (daclizumab) for organ transplant patients on long-term, maintenance therapy. Under the terms of the expanded deal, PDL will receive an upfront payment of $10 million and may receive up to $145 million in milestone payments.

Roche, which currently markets Zenapax for induction therapy in organ transplant patients, said it will continue to manufacture and promote Zenapax exclusively worldwide, and the two companies will share global development costs under the terms of the expanded partnership. PDL will have the option to co-promote the treatment for transplant maintenance in the US, and will receive royalties on net sales of the product for this indication outside the US, news sources report.

The drugmakers are developing a subcutaneous formulation of the drug, to be used in Phase II trials that are expected to begin in 2006.

To read more Top Story articles, click here.